Publications en collaboration avec des chercheurs de Hospital Universitario de la Princesa (23)

2022

  1. Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours

    Scientific reports, Vol. 12, Núm. 1, pp. 2671

2021

  1. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas

    Hormones, Vol. 20, Núm. 4, pp. 735-744

  2. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas

    Journal of Endocrinological Investigation, Vol. 44, Núm. 11, pp. 2349-2357

  3. Predictors of tumour growth and autonomous cortisol secretion development during follow-up in non-functioning adrenal incidentalomas

    Journal of Clinical Medicine, Vol. 10, Núm. 23

2013

  1. Efecto adverso excepcional de la suspensión del tratamiento con levotiroxina para la ablación con I-131 del remanente tiroideo en una paciente con cáncer diferenciado de tiroides

    Endocrinologia y Nutricion

2012

  1. Cost of clinical management of acromegaly in Spain

    Clinical Drug Investigation, Vol. 32, Núm. 4, pp. 235-245

2011

  1. Estudio OASIS: Manejo terapéutico de la acromegalia en un escenario de práctica clínica habitual. Evaluación de la eficacia de las diversas estrategias de tratamiento aplicadas

    Endocrinologia y Nutricion, Vol. 58, Núm. 9, pp. 478-486

  2. Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study

    Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2

2010

  1. Metástasis en la glándula tiroidea

    Cirugia Espanola

  2. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154

  3. Recurrent hyponatremia as the presenting feature of a pituitary abscess: A case report

    Endocrinologia y Nutricion

  4. The efficacy of octreotide lar as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: Predictive factors of tumor and biochemical response

    Hormone and Metabolic Research, Vol. 42, Núm. 1, pp. 38-44

  5. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229

2009

  1. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients

    Obesity, Vol. 17, Núm. 1, pp. 3-9

  2. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome

    Fertility and Sterility, Vol. 91, Núm. 6, pp. 2527-2536

2008

  1. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: Effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin

    Human Reproduction, Vol. 23, Núm. 7, pp. 1594-1601

2007

  1. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome

    Human Reproduction, Vol. 22, Núm. 12, pp. 3197-3203

  2. Fibrosis quística, bocio e hipertiroidismo

    Endocrinologia y Nutricion, Vol. 54, Núm. 2, pp. 125-128

  3. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 92, Núm. 6, pp. 2141-2148

2006

  1. Genomic variants in polycystic ovary syndrome

    Clinica Chimica Acta, Vol. 366, Núm. 1-2, pp. 14-26